Medicare Coverage Of Aduhelm To Treat Alzheimer’s Disease Will Be Limited To Clinical Trials & Comparative Studies

On April 7, 2022, the federal Centers for Medicare & Medicaid Services (CMS) finalized a final Medicare national coverage determination (NCD) that applies to Aduhelm, a new medication approved by the FDA to treat cognitive symptoms of Alzheimer’s disease (AD). Medicare will cover the medication class—monoclonal antibodies directed against amyloid—when used for clinical trials and comparative studies for beneficiaries with mild cognitive impairment (MCI) or dementia, when either condition is due to AD. Study participants with either condition must have confirmed presence of amyloid beta plaques in the brain consistent with AD.

The final NCD is for . . .